- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT04834414
Avkjølte blodplateundersøkelse "CHIPS" (CHIPS)
Studie av avkjølte blodplater
A phase 3 randomized partial blind storage duration ranging study in patients undergoing complex cardiac surgery that will compare the transfusion of cold stored platelets to standard room temperature stored platelets. The primary objective is to establish that cold stored platelets have a non-inferiority (or superiority) to room temperature platelets.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Studietype
Registrering (Faktiske)
Fase
- Fase 3
Kontakter og plasseringer
Studiesteder
-
-
Western Australia
-
Murdoch, Western Australia, Australia, 6150
- Fiona Stanley Hospital
-
Nedlands, Western Australia, Australia, 6009
- Sir Charles Gairdner Hospital
-
-
-
-
Arizona
-
Pheonix, Arizona, Forente stater, 85054
- Mayo Clinic Arizona
-
Tuscon, Arizona, Forente stater, 85713
- Banner University Medical Center
-
-
California
-
Los Angeles, California, Forente stater, 90095
- Ronald Reagan UCLA Medical Center
-
-
Florida
-
Gainesville, Florida, Forente stater, 32608
- University of Florida
-
-
Illinois
-
Chicago, Illinois, Forente stater, 60611
- Northwestern Memorial Hospital
-
Maywood, Illinois, Forente stater, 60153
- Loyola Universtiy Medical Center
-
-
Kansas
-
Kansas City, Kansas, Forente stater, 66103
- University of Kansas Medical Center
-
-
Kentucky
-
Lexington, Kentucky, Forente stater, 40536
- University of Kentucky
-
-
Maryland
-
Baltimore, Maryland, Forente stater, 21287
- John Hopkins
-
-
Michigan
-
Ann Arbor, Michigan, Forente stater, 48109
- University of Michigan
-
-
Minnesota
-
Minneapolis, Minnesota, Forente stater, 55455
- University of Minnesota
-
Rochester, Minnesota, Forente stater, 55905
- Mayo Clinic
-
-
North Carolina
-
Winston-Salem, North Carolina, Forente stater, 27157
- Wake Forest
-
-
Ohio
-
Cincinnati, Ohio, Forente stater, 45229
- Cincinnati Children's Hospital
-
-
Oregon
-
Portland, Oregon, Forente stater, 97239
- Oregon Health and Science University
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Forente stater, 19104
- Children's Hospital of Philadelphia
-
Pittsburgh, Pennsylvania, Forente stater, 15232
- University of Pittsburgh Medical Center
-
-
Rhode Island
-
Providence, Rhode Island, Forente stater, 02910
- Rhode Island Hospital
-
-
Texas
-
Dallas, Texas, Forente stater, 75235
- University of Texas Children's Medical Center
-
Dallas, Texas, Forente stater, 75235
- University of Texas Medical Center Clements
-
Houston, Texas, Forente stater, 77030
- Memorial Hermann Texas Medical Center
-
Houston, Texas, Forente stater, 77030
- Baylor Texas Children's
-
-
Wisconsin
-
Madison, Wisconsin, Forente stater, 53792
- University of Wisconsin- Madison
-
Milwaukee, Wisconsin, Forente stater, 53226
- Children's Hospital of Wisconsin
-
Milwaukee, Wisconsin, Forente stater, 53215
- Aurora St. Luke's Medical Center
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Viable neonates ≥ 3 kg at time of enrollment (as defined in Section 4.1) OR age greater than 28 days and less than 85 years of age at time of consent; AND
- Planned complex cardiac surgery with planned use of cardiopulmonary bypass, with an expectation of bleeding requiring platelet transfusion.
Exclusion Criteria:
- Expected order for washed or volume reduced platelets
- Patient with known anti-platelet antibodies
- Platelet transfusion refractoriness due to anti-HLA antibodies
- Known or suspected pregnancy
- Previously randomized in this study
- Conscious objection or unwillingness to receive blood products
- Known IgA deficiency
- Known congenital platelet disorder
- Known congenital bleeding disorder
- Planned post-operative extracorporeal membrane oxygenation (ECMO), ventricular assist device (VAD), and/or continuous renal replacement therapy (CRRT)/ hemodialysis
- Patients intended to receive whole blood either intra-operative or post-operative for bleeding
- Platelet transfusion (of any type) within 24 hours prior to the date of surgery
- Pre-operative thrombocytopenia, defined as platelet count <75x10(9)/L, based on the most recent labs completed within 72 hours prior to the date of surgery.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Sekvensiell tildeling
- Masking: Trippel
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Aktiv komparator: Room Temperature Platelets
Platelets stored at 20-24 degrees Celsius |
Platelets stored at 20-24 degrees Celsius |
|
Eksperimentell: Cold Stored Platelets
Platelets stored at 1-6 degree Celsius |
Platelets stored at 1-6 degree Celsius |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Hemostatic Efficacy
Tidsramme: 24 hours after first study platelet transfusion
|
Assessed by a bleeding score, a modified Peri-Operative bleeding score: the score ranges from 1-5. A lower score signifies a better outcome. |
24 hours after first study platelet transfusion
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Chest Tube Output Through 24 Hours
Tidsramme: 24 hours from first study platelet transfusion or ICU admit (determined from which occurs last)
|
Chest tube output will be assessed by volume |
24 hours from first study platelet transfusion or ICU admit (determined from which occurs last)
|
Andre resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Blood Product Administration
Tidsramme: 24 and 72 hours from start time of first study platelet transfusion
|
The quantity of RBCs, Plasma, Platelets, Cryoprecipitate, and Whole blood |
24 and 72 hours from start time of first study platelet transfusion
|
|
Transfusion Associated Adverse Events
Tidsramme: within 7 days of first study platelet transfusion
|
As per CDC guidelines for transfusion associated adverse events |
within 7 days of first study platelet transfusion
|
|
Arterial Thrombotic Event
Tidsramme: within 7 days of first study platelet transfusion
|
Stroke, MI, aortic thromboic even |
within 7 days of first study platelet transfusion
|
|
Venous Thrombotic Event
Tidsramme: within 7 days of first study platelet transfusion
|
Deep vein thrombosis or pulmonary embolism confirmed by ultrasound, venography, perfusion scan, spiral CT, MRI, or pulmonary angiogram |
within 7 days of first study platelet transfusion
|
|
All Cause Mortality
Tidsramme: up to 28 days
|
Death for any reason |
up to 28 days
|
|
Total Dose of Individual Hemostatic Adjuncts (Units/kg)
Tidsramme: 24 and 72 hours from start time of first study platelet transfusion
|
Antifibrinolytic and coagulation factor concentrates |
24 and 72 hours from start time of first study platelet transfusion
|
|
Total Dose of Individual Hemostatic Adjuncts (mcg/kg)
Tidsramme: 24 and 72 hours from start time of first study platelet transfusion
|
Antifibrinolytic and coagulation factor concentrates |
24 and 72 hours from start time of first study platelet transfusion
|
|
Total Dose of Individual Hemostatic Adjuncts (mg/kg)
Tidsramme: 24 and 72 hours from start time of first study platelet transfusion
|
Antifibrinolytic and coagulation factor concentrates |
24 and 72 hours from start time of first study platelet transfusion
|
|
Total Dose of Individual Hemostatic Adjuncts (Grams/kg)
Tidsramme: 24 and 72 hours from start time of first study platelet transfusion
|
Antifibrinolytic and coagulation factor concentrates Epsilon-amino-caproic acid |
24 and 72 hours from start time of first study platelet transfusion
|
|
Mechanical Ventilation
Tidsramme: up to 28 days after first study platelet transfusion
|
Number of participants with need for mechanical ventilation |
up to 28 days after first study platelet transfusion
|
|
Length of Stay
Tidsramme: up to 28 days
|
ICU and hospital length of stay |
up to 28 days
|
|
Relative Change in Hemostatic Parameters at 6 and 24 Hours - Hemoglobin
Tidsramme: 6 and 24 hours after first study platelet transfusion
|
Relative change = (post transfusion measurement - pre transfusion measurement)/(pre transfusion measurement) |
6 and 24 hours after first study platelet transfusion
|
|
Relative Change in Hemostatic Parameters at 6 and 24 Hours - Hematocrit
Tidsramme: 6 and 24 hours after first study platelet transfusion
|
Relative change = (post transfusion measurement - pre transfusion measurement)/(pre transfusion measurement). |
6 and 24 hours after first study platelet transfusion
|
|
Relative Change in Hemostatic Parameters at 6 and 24 Hours- Platelet Count
Tidsramme: 6 and 24 hours after first study platelet transfusion
|
Relative change = (post transfusion measurement - pre transfusion measurement)/(pre transfusion measurement) |
6 and 24 hours after first study platelet transfusion
|
|
Relative Change in Hemostatic Parameters at 6 and 24 Hours- INR
Tidsramme: 6 and 24 hours after first study platelet transfusion
|
Relative change = (post transfusion measurement - pre transfusion measurement)/(pre transfusion measurement) |
6 and 24 hours after first study platelet transfusion
|
|
Relative Change in Hemostatic Parameters at 6 and 24 Hours- PTT
Tidsramme: 6 and 24 hours after first study platelet transfusion
|
Relative change = (post transfusion measurement - pre transfusion measurement)/(pre transfusion measurement) |
6 and 24 hours after first study platelet transfusion
|
|
Relative Change in Hemostatic Parameters at 6 and 24 Hours- Fibrinogen
Tidsramme: 6 and 24 hours after first study platelet transfusion
|
Relative change = (post transfusion measurement - pre transfusion measurement)/(pre transfusion measurement) |
6 and 24 hours after first study platelet transfusion
|
|
Unplanned Sternal Closure Delay
Tidsramme: prior to ICU admission
|
Sternum left open after cardiac surgery |
prior to ICU admission
|
|
Re-exploration for Bleeding
Tidsramme: 24 hours first study platelet transfusion
|
Return to OR after ICU admission |
24 hours first study platelet transfusion
|
|
Unplanned Extracorporeal Support Post Operatively
Tidsramme: within 48 hours of first study platelet transfusion
|
Unplanned placement on ECMO post operatively within 48 hours of 1st transfusion |
within 48 hours of first study platelet transfusion
|
|
Morbidities After ICU Admission
Tidsramme: within 7 days of first study platelet transfusion
|
Acute respiratory distress syndrome, need for and duration of renal support, renal failure, septic shock |
within 7 days of first study platelet transfusion
|
|
Measures of End Organ Injury- BUN and Creatinine
Tidsramme: within 48 hours of first study platelet transfusion worst value
|
If BUN, creatinine are collected clinically.- worst value |
within 48 hours of first study platelet transfusion worst value
|
|
Measures of End Organ Injury- Lactate
Tidsramme: within 48 hours of first study platelet transfusion worst value
|
If lactate was collected clinically. Worst value |
within 48 hours of first study platelet transfusion worst value
|
|
Measures of End Organ Injury- Troponin
Tidsramme: within 48 hours of first study platelet transfusion.
|
If lactate was collected clinically. Worst value |
within 48 hours of first study platelet transfusion.
|
|
Measures of End Organ Injury- ALT and AST
Tidsramme: within 48 hours of first study platelet transfusion.
|
If lactate was collected clinically. Worst value |
within 48 hours of first study platelet transfusion.
|
Samarbeidspartnere og etterforskere
Sponsor
Samarbeidspartnere
Etterforskere
- Studieleder: Philip C Spinella, MD, University of Pittsburgh
- Studieleder: Marie E Steiner, MD, University of Minnesota
- Studieleder: Nicole D Zantek, MD, University of Minnesota
Publikasjoner og nyttige lenker
Generelle publikasjoner
- Krachey E, Viele K, Spinella PC, Steiner ME, Zantek ND, Lewis RJ. The design of an adaptive clinical trial to evaluate the efficacy of platelets stored at low temperature in surgical patients. J Trauma Acute Care Surg. 2018 Jun;84(6S Suppl 1):S41-S46. doi: 10.1097/TA.0000000000001876.
- Strandenes G, Sivertsen J, Bjerkvig CK, Fosse TK, Cap AP, Del Junco DJ, Kristoffersen EK, Haaverstad R, Kvalheim V, Braathen H, Lunde THF, Hervig T, Hufthammer KO, Spinella PC, Apelseth TO. A Pilot Trial of Platelets Stored Cold versus at Room Temperature for Complex Cardiothoracic Surgery. Anesthesiology. 2020 Dec 1;133(6):1173-1183. doi: 10.1097/ALN.0000000000003550.
- Zantek ND, Steiner ME, VanBuren JM, Lewis RJ, Berry NS, Viele K, Krachey E, Dean JM, Nelson S, Spinella PC. Design and logistical considerations for the randomized adaptive non-inferiority storage-duration-ranging CHIlled Platelet Study. Clin Trials. 2023 Feb;20(1):36-46. doi: 10.1177/17407745221126423. Epub 2022 Dec 21.
- Spinella PC, Zantek ND, VanBuren JM, Nicolson SC, Khanna AK, Klompas AM, Boisen ML, Williams TM, Monteleone M, Bashir DA, Pavey W, Smith BB, Ahmed MI, Niebler RA, Jeng E, Flynn BC, Joshi RV, Preuss JF, Goswami D, Yamada C, Lewis C, Cohn CS, Tint H, Kwak J, Sodha N, Simon ER, Van PY, Greilich PE, Booth FVM, Carter CP, Keegan A, Cap AP, Matuk J, McGlothlin A, Berry NS, Lewis RJ, Steiner ME; CHIPS Investigator Group. Cold and Room-Temperature Platelets in Cardiac Surgery: The CHIPS Randomized Clinical Trial. JAMA. 2026 Aug 17. doi: 10.1001/jama.2026.13328. Online ahead of print.
- Lewis AR, Peffley N, Klompas AM, Ashrani AA. Role of individual factor X concentrate pharmacokinetic studies in perioperative management of AL amyloidosis-associated acquired factor X deficiency. Transfusion. 2023 Sep;63(9):1773-1777. doi: 10.1111/trf.17477. Epub 2023 Jul 10.
- Klompas AM, Stubbs J. Massive transfusion protocol: What's in a name? Transfusion. 2023 Apr;63(4):896-897. doi: 10.1111/trf.17297. No abstract available.
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- CHIPS
- W81XWH2090021 (Annet stipend/finansieringsnummer: DoD)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .